Editorial: lean and obese NAFLD—similar siblings (English)
- New search for: Mellor, T. E.
- New search for: Torres, D. M.
- New search for: Mellor, T. E.
- New search for: Torres, D. M.
In:
Alimentary Pharmacology & Therapeutics
;
46
, 5
;
549-550
;
2017
- Article (Journal) / Electronic Resource
-
Title:Editorial: lean and obese NAFLD—similar siblings
-
Contributors:Mellor, T. E. ( author ) / Torres, D. M. ( author )
-
Published in:Alimentary Pharmacology & Therapeutics ; 46, 5 ; 549-550
-
Publisher:
-
Publication date:2017-09-01
-
Size:2 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Source:
Table of contents – Volume 46, Issue 5
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 479
-
Systematic review with meta‐analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infectionQuraishi, M. N. / Widlak, M. / Bhala, N. / Moore, D. / Price, M. / Sharma, N. / Iqbal, T. H. et al. | 2017
- 494
-
Review article: new treatments in non‐alcoholic fatty liver diseaseTownsend, S. A. / Newsome, P. N. et al. | 2017
- 508
-
The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre‐surgical factorsYanai, H. / Ben‐Shachar, S. / Mlynarsky, L. / Godny, L. / Leshno, M. / Tulchinsky, H. / Dotan, I. et al. | 2017
- 516
-
The development of a magnetic resonance imaging index for fistulising Crohn's diseaseSamaan, M. A. / Puylaert, C. A. J. / Levesque, B. G. / Zou, G. Y. / Stitt, L. / Taylor, S. A. / Shackelton, L. M. / Vandervoort, M. K. / Khanna, R. / Santillan, C. et al. | 2017
- 529
-
Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptomsPolster, A. / Van Oudenhove, L. / Jones, M. / Öhman, L. / Törnblom, H. / Simrén, M. et al. | 2017
- 540
-
Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patientsCurry, M. P. / Tapper, E. B. / Bacon, B. / Dieterich, D. / Flamm, S. L. / Guest, L. / Kowdley, K. V. / Lee, Y. / Milligan, S. / Tsai, N. et al. | 2017
- 549
-
Editorial: lean and obese NAFLD—similar siblingsMellor, T. E. / Torres, D. M. et al. | 2017
- 550
-
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pyloriFraser, A. G. et al. | 2017
- 551
-
Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori—authors’ replyJung, Y. S. / Kim, E. H. / Park, C. H. et al. | 2017
- 552
-
Editorial: selective serotonin receptor inhibitors and gastrointestinal bleeding—managing the riskVakil, Nimish et al. | 2017
- 553
-
Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial careKeefer, L. et al. | 2017
- 554
-
Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care—authors’ replyAlexakis, C. / Kumar, S. / Saxena, S. / Hotopf, M. / Pollok, R. et al. | 2017
- 555
-
Editorial: how effective is vedolizumab in the ‘real world’?Speight, R. A. / Mansfield, J. C. et al. | 2017
- 556
-
Editorial: oesophageal dilation in eosinophilic oesophagitis—can and should, but when and how?Kia, L. / Hirano, I. et al. | 2017
- 558
-
Editorial: oesophageal dilation in eosinophilic oesophagitis—can and should, but when and how? Authors’ replyMoawad, F. J. / Lucendo, A. J. / Molina‐Infante, J. et al. | 2017
- 559
-
Editorial: progress towards a simple tool for screening for hepatic steatosis in the general populationGallacher, J. / McPherson, S. et al. | 2017
- 560
-
Editorial: progress towards a simple tool for screening for hepatic steatosis in the general population – authors’ replyYip, T. C.‐F. / Ma, A. J. / Yuen, P.‐C. / Wong, G. L.‐H. et al. | 2017
- 562
-
Letter: role of tenofovir to prevent mother‐to‐child transmission of hepatitis B virusZhang, C.‐Y. / Ahir, B.‐K. / Wu, G‐B. / Zhong, J.‐H. / Li, L.‐Q. et al. | 2017
- 563
-
Letter: role of tenofovir to prevent mother‐to‐child transmission of hepatitis B virus—authors’ replyLee, Y.‐S. / Hyun, M. H. / Kim, J. H. / Yeon, J. E. / Byun, K. S. et al. | 2017
- 564
-
Letter: a potassium‐competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection‐induced artificial ulcers after treatment of gastric neoplasmsBan, H. / Sugimoto, M. / Otsuka, T. / Murata, M. / Nakata, T. / Hasegawa, H. / Fukuda, M. / Inatomi, O. / Bamba, S. / Kushima, R. et al. | 2017
- 566
-
Letter: a potassium‐competitive acid blocker vs a proton pump inhibitor for healing endoscopic submucosal dissection‐induced artificial ulcers after treatment of gastric neoplasms—authors’ replyKagawa, T. / Iwamuro, M. / Inaba, T. et al. | 2017
- 566
-
Letter: non‐alcoholic fatty liver disease and polycystic ovary syndrome—evidence for low vitamin D status contributing to the linkPang, Q. / Zhou, L. / Jin, H. / Man, Z. R. / Liu, H. C. et al. | 2017